Loss of CDX-2 expression is an independent poor prognostic biomarker in patients with early-stage deficient mismatch repair colorectal cancer.

Krittiya KorphaisarnKanjana SukhokanjanachusakAnanya PongpaibulVitoon ChinswangwatanakulCharuwan Akewanlop

Published in: Asia-Pacific journal of clinical oncology (2021)

Loss of CDX-2 expression was found to be associated with right-sided tumor, dMMR status, and BRAF mutation. Moreover, loss of CDX-2 expression is a poor prognostic factor for OS in stage I-III, even among patients with dMMR tumors.

Keyphrases

poor prognosis
early stage
prognostic factors
binding protein
squamous cell carcinoma
radiation therapy
metastatic colorectal cancer